- Home
- SONO vs IRON Comparison
SONO vs IRON Comparison
Compare SONO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- IRON
- Stock Information
- Founded
- SONO 2002
- IRON 2017
- Country
- SONO United States
- IRON United States
- Employees
- SONO N/A
- IRON N/A
- Industry
- SONO Consumer Electronics/Video Chains
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- IRON Health Care
- Exchange
- SONO Nasdaq
- IRON Nasdaq
- Market Cap
- SONO 1.7B
- IRON 1.9B
- IPO Year
- SONO 2018
- IRON N/A
- Fundamental
- Price
- SONO $11.20
- IRON $52.41
- Analyst Decision
- SONO Buy
- IRON Strong Buy
- Analyst Count
- SONO 2
- IRON 10
- Target Price
- SONO $14.50
- IRON $79.10
- AVG Volume (30 Days)
- SONO 1.9M
- IRON 327.4K
- Earning Date
- SONO 05-06-2025
- IRON 02-27-2025
- Dividend Yield
- SONO N/A
- IRON N/A
- EPS Growth
- SONO N/A
- IRON N/A
- EPS
- SONO N/A
- IRON N/A
- Revenue
- SONO $1,456,044,000.00
- IRON N/A
- Revenue This Year
- SONO N/A
- IRON N/A
- Revenue Next Year
- SONO $7.21
- IRON N/A
- P/E Ratio
- SONO N/A
- IRON N/A
- Revenue Growth
- SONO N/A
- IRON N/A
- 52 Week Low
- SONO $10.23
- IRON $25.60
- 52 Week High
- SONO $19.76
- IRON $68.86
- Technical
- Relative Strength Index (RSI)
- SONO 27.89
- IRON 38.87
- Support Level
- SONO $12.68
- IRON $52.35
- Resistance Level
- SONO $13.26
- IRON $56.29
- Average True Range (ATR)
- SONO 0.55
- IRON 2.50
- MACD
- SONO -0.14
- IRON -0.05
- Stochastic Oscillator
- SONO 0.94
- IRON 1.24
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.